New Content  edit
Get The App!

Quizartinib Improves Survival in Patients with FLT3-ITD mutated R/R AML: QuANTUM-R trial
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
Presented by Mark J. Levis, MD, PhD Dr. Levis presents results of the QuANTUM-R trial, the first positive phase 3 trial to demonstrate improved OS with single-agent quizartinib in the R/R FLT3-ITD AML setting compared with salvage chemotherapy. The data confirm the safety and efficacy of quizartinib and the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor.


REGISTER NOW TO ACCESS THIS EPISODE'S FREE RESOURCE DOWNLOADS AND TRANSCRIPTS, AS WELL AS VIEW 150+ FREE EPISODES IN ACUTE LEUKEMIA AND MORE - ALL OPTIMIZED FOR YOUR MOBILE LEARNING.

MEDED ON THE GO

SIMPLY THE SMARTEST WAY TO LEARN